Table 2 Comparisons of clinical, biological and haemodynamic characteristics between patients who developed or not CA-AKI
CA-AKI (n = 23) | No CA-AKI (n = 126) | P value | |
|---|---|---|---|
Age (years) | 65 [55–78] | 64 [56–72] | 0.43 |
Sex (male/female) | 16/7 | 76/50 | 0.41 |
ICU admission diagnosis (medical/surgical) | 20/3 | 93/33 | 0.18 |
APACHE II score | 25 [18–30] | 19 [14–24] | 0.006 |
Weight (kg) | 80 [70–90] | 78 [70–90] | 0.91 |
Diabetes mellitus (%) | 6 (26) | 35 (28) | 0.87 |
Cardiovascular risk factors (%) | 17 (74) | 87 (69) | 0.64 |
Need for renal replacement (%) | 3 (13) | 3 (2) | 0.02 |
Length of ICU stay (days) | 13 [6–18] | 12 [7–22] | 0.99 |
ICU mortality (%) | 12 (52) | 23 (19) | <0.001 |
Haematocrit (%) | 31.5 [27.3–33.5] | 31.4 [27.0–38.2] | 0.78 |
Urea (mg/dL) | 47.9 [35.2–56.4] | 44.1 [31.8–58.5] | 0.63 |
Creatinine (mg/dL) | 1.08 [0.61–1.34] | 0.89 [0.64–1.10] | 0.26 |
MDRD (mL/min/1.73 m2) | 61.0 [49.4–105.0] | 79.4 [57.4–116.0] | 0.15 |
Patients with creatinine ≥1.5 mg/dL (%) | 3 (13 %) | 12 (9.5 %) | 0.61 |
pH | 7.37 [7.28–7.47] | 7.40 [7.33–7.46] | 0.39 |
BE (meq/L) | −1.5 [−4.0 − 3.0] | 0.0 [−3.0–4.0] | 0.38 |
HCO3 (mg/dL) | 23.6 [20.7–31.3] | 25.3 [23.0–29.3] | 0.54 |
Na (mEq/L) | 138 [134–142] | 139 [137–143] | 0.14 |
Lactate (mmol/L) | 0.7 [0.5–1.3] | 0.5 [0.4–0.8] | 0.02 |
Nephropathy prevention (%) | 3 (13) | 26 (20) | 0.40 |
Mean blood pressure before CM (mmHg) | 79 [62–89] | 81 [72–93] | 0.15 |
Mean blood pressure at 6 h post CM injection (mmHg) | 73 [67–82] | 81 [70–94] | 0.056 |
Mean blood pressure at 12 h post CM injection (mmHg) | 73 [66–76] | 77 [71–88] | 0.012 |
Mean blood pressure at 24 h post CM injection (mmHg) | 78 [71–87] | 79 [70–94] | 0.092 |
Mean blood pressure at 48 h post CM injection (mmHg) | 75 [68–90] | 85 [77–98] | 0.001 |
Mean blood pressure at 72 h post CM injection (mmHg) | 76 [70–87] | 85 [75–100] | 0.008 |
CVP before CM (mmHg) | 13 [8–14] | 9 [6–11] | 0.12 |
Maximal vasopressor dose before CM (mcg/kg/min) | 0.07 [0.00–0.20] | 0.00 [0.00–0.05] | 0.001 |
Maximal vasopressor dose day 1 (mcg/kg/min) | 0.07 [0.00–0.26] | 0.00 [0.00–0.00] | <0.001 |
Maximal vasopressor dose day 2 (mcg/kg/min) | 0.04 [0.00–0.35] | 0.00 [0.00–0.00] | <0.001 |
Maximal vasopressor dose day 3 (mcg/kg/min) | 0.03 [0.00–0.29] | 0.00 [0.00–0.00] | <0.001 |
Doses of CM (ml/kg) | 1.71 [1.44–3.47] | 1.60 [1.30–2.00] | 0. 14 |
Nephrotoxic drugs (%) | 9 (39.1) | 57 (46.3) | 0.59 |
Diuretics on day of CM injection (%) | 5 (21.7) | 19 (15.1) | 0.43 |
Fluid intake, day 0 (ml) | 2950 [1975–3060] | 2825 [1975–3060] | 0.74 |
Fluid intake, day 1 (ml) | 2982 [2047–3945] | 2948 [2080–3685] | 0.71 |
Fluid intake, day 2 (ml) | 2455 [1807–3756] | 2648 [2010–3305] | 0.99 |
Fluid intake, day 3 (ml) | 2695 [1877–3678] | 2340 [1643–3283] | 0.34 |